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Summary
 
Granzyme B (GraB) is required for the efficient activation of apoptosis by cytotoxic T lympho-
cytes and natural killer cells. We find that GraB and perforin induce severe mitochondrial per-
turbation as evidenced by the release of cytochrome 
 
c
 
 into the cytosol and suppression of trans-
membrane potential (
 
Dc
 
). The earliest mitochondrial event was the release of cytochrome 
 
c
 
,
which occurred at the same time as caspase 3 processing and consistently before the activation
of apoptosis. Granzyme K/perforin or perforin treatment, both of which kill target cells effi-
ciently but are poor activators of apoptosis in short-term assays, did not induce rapid cyto-
chrome 
 
c
 
 release. However, they suppressed 
 
Dc
 
 and increased reactive oxygen species genera-
tion, indicating that mitochondrial dysfunction is also associated with this nonapoptotic cell
death.
Pretreatment with peptide caspase inhibitors zVAD-FMK or YVAD-CHO prevented GraB
apoptosis and cytochrome 
 
c
 
 release, whereas DEVD-CHO blocked apoptosis but did not pre-
vent cytochrome 
 
c
 
 release, indicating that caspases act both up- and downstream of mitochon-
dria. Of additional interest, 
 
Dc
 
 suppression mediated by GraK or GraB and perforin was not
affected by zVAD-FMK and thus was caspase independent. Overexpression of Bcl-2 and
Bcl-X
 
L
 
 suppressed caspase activation, mitochondrial cytochrome 
 
c
 
 release, 
 
Dc
 
 suppression, and
apoptosis and cell death induced by GraB, GraK, or perforin.
In an in vitro cell free system, GraB activates nuclear apoptosis in S-100 cytosol at high
doses, however the addition of mitochondria amplified GraB activity over 15-fold. GraB-
induced caspase 3 processing to p17 in S-100 cytosol was increased only threefold in the pres-
ence of mitochondria, suggesting that another caspase(s) participates in the mitochondrial am-
plification of GraB apoptosis. We conclude that GraB-induced apoptosis is highly amplified by
mitochondria in a caspase-dependent manner but that GraB can also initiate caspase 3 process-
ing and apoptosis in the absence of mitochondria.
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ytotoxic lymphocytes can kill their target cells either
through activation of the Fas receptor (1) or by the ac-
tion of granule proteins granzyme B (GraB)
 
1
 
 and perforin
(2, 3). Both mechanisms activate the cysteine aspartyl pro-
teases (caspases) that are the effector proteases of apoptosis,
which ultimately lead to the disassembly of the cell through
hydrolysis of cytoplasmic and nuclear proteins (4, 5). Fas
interacts directly with caspases through a linker molecule at
the cell membrane (6, 7), whereas GraB enters the cyto-
plasm and initiates processing of caspases after perforin sig-
naling (8–10). GraB activates apoptosis through its ability
to cleave proteins after an aspartic acid (11, 12) similar to
caspases (13), and can directly cleave in vitro translated
caspases 3, 7, 8, and 10 between the large and small subunit
(4). This initial processing of the caspase protein is followed
by autocatalytic removal of the prodomain and tetramer as-
sembly into the mature protein (14, 15).
The proteolytic specificity of caspases can be separated
into at least three subgroups (13). The caspases 2, 3, 7 sub-
family proteases have a preference for an aspartic acid in the
 
1
 
Abbreviations used in this paper:
 
 BA, bongkrekic
 
 
 
acid; CsA, cyclosporine
acid; 
 
Dc
 
, mitochondrial transmembrane potential; DEVD-CHO, Ac-
Asp-Glu-Val-Asp-acid aldehyde; FA-FMK, Cbz-Phe-Ala-fluoromethyl
ketone; GraB, granzyme B; GraK, granzyme K; PT, permeability transi-
tion; Rh123, Rhodamine 123; ROS, reactive oxygen species; YVAD-
CHO, Ac-Tyr-Val-Ala-Asp-acid aldehyde; zVAD-FMK, Cbz-Val-Ala-
Asp-fluoromethyl ketone. 
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P4 position and are considered downstream in the caspase
cascade (4, 13). IL-1
 
b
 
–converting enzyme (ICE) subfamily
proteases differ from the first group by recognition of a bulky
amino acid (Trp, Tyr) in the P4 position. A third group pre-
fers leucine/isoleucine/valine in P4, including caspases 6, 8,
9, and probably 10, all of which are upstream caspases. This
latter recognition sequence is shared with GraB. In the Fas
activation pathway, caspase 8 interacts with Fas through
FADD/Mort (6, 7) and is therefore upstream on the cell
death pathway, whereas other caspases including caspase 3
are activated by caspase 8 (16) and are downstream.
Since GraB can process and activate caspase 10, 8, 7, and
3 in vitro
 
 
 
and in vivo (17–20), it may be able to initiate apop-
tosis by activating either upstream or downstream caspases
within the cell death pathway. However, recent work sug-
gests that mitochondria play an important if not key role in
the regulation of apoptosis (21–26). Mitochondrial func-
tion is disturbed early in the apoptotic response and may be
important in propagating death signals. Mitochondria re-
lease cytochrome 
 
c
 
 (25, 26), which interacts with Apaf-1,
the recently cloned Ced-4 homologue in humans (27). In
the presence of dATP (24), Apaf-1 and cytochrome 
 
c
 
 can
activate caspase 9 and then caspase 3 (28). Another mito-
chondrial event associated with apoptosis is the loss of
transmembrane potential (
 
Dc
 
), which is seen early in re-
sponse to an apoptotic signal and is thought to occur as the
result of the opening of mitochondrial permeability transi-
tion (PT) pores (22–24).
Bcl-2 in the outer mitochondrial membrane, and to a
lesser extent as a free cytosolic protein, is important for the
suppression of apoptosis and mitochondrial manifestations of
apoptosis (29–31). The 
 
Caenorhabditis elegans
 
 Bcl-2 homo-
logue Ced-9 forms a complex with Ced-4 and the caspase
Ced-3, and this complex can regulate Ced-3 activation (32,
33). Bcl-2 also suppresses cytochrome 
 
c
 
 (27, 28) and apopto-
sis-inducing factor (34) release from mitochondria, which
prevents the activation of caspases. Bcl-2 has been reported
to inhibit GraB-induced apoptosis (35) as well as CTL apop-
tosis mediated by granules (granzymes and perforin) (36, 37).
Because GraB can cleave and activate both up- and
downstream caspases, it has been generally assumed that
once this is accomplished the caspase cascade will continue
to amplify itself and hydrolyze the relevant substrates in
the cytoplasm and nucleus to complete apoptosis. Such a
scheme would exclude the participation of mitochondria
and the mitochondrial amplification mechanisms. We have
attempted to determine whether or not GraB is truly as ef-
ficient as the in vitro data would suggest and bypass mito-
chondria. We report here the existence of a mitochondrial-
regulated, caspase-dependent GraB apoptotic cell death
pathway. In addition, we find that caspase-independent cell
death induced by perforin and perforin/granzyme treat-
ment is also associated with mitochondrial dysfunction.
 
Materials and Methods
 
Cell Lines and Reagents.
 
The cell lines HeLa, Rat-1, U937,
and the Bcl-2 transfectant Rat-1/Bcl-2, as well as U937 trans-
fected with Bcl-2 and Bcl-X
 
L
 
, were maintained in 
 
a
 
-MEM
(GIBCO BRL) supplemented with 10% fetal bovine serum
(GIBCO BRL). The peptide aspartyl caspase inhibitor Cbz-Val-
Ala-Asp-fluoromethyl ketone (zVAD-FMK), and control pep-
tides Cbz-Phe-Ala-fluoromethyl ketone (FA-FMK) (Enzyme
System Products), Ac-Asp-Glu-Val-Asp-acid aldehyde (DEVD-
CHO), and Ac-Tyr-Val-Ala-Asp-acid aldehyde (YVAD-CHO)
(Peptide International, Louisville, KY) were prepared as 10-mM
stock solutions in DMSO. Bongkrekic acid (BA) was provided by
Dr. J.A. Duine (Delft University, Delft, The Netherlands). Cy-
closporine A (CsA) was purchased from Sigma Chemical Co.
GraB, GraK, and perforin were purified from the granules of a rat
NK large granular lymphocyte leukemia cell line using a previ-
ously described procedure (11). Recombinant GraB was prepared
from a baculovirus expression system as previously described (38).
A mutant murine GraB in which the active Ser
 
203
 
 was converted
to an alanine was generated by PCR mutagenesis using the fol-
lowing primers: sense primer 5
 
9
 
-TCCTTTCGGGGGGATGCT-
GGAGGCCCGCTTGTG-3
 
9
 
 and antisense primer 5
 
9
 
-CACAAG-
CGGGCCTCCAGCATCCCCCCGAAAGGA-3
 
9
 
. The mutant
protein was expressed and purified by the same method (38).
 
Perforin and Granzyme-mediated Cell Death.
 
Cell lines used in
this study were treated with perforin and either of the purified
granzymes as previously described (11). In brief, target cells in
HBSS/0.4% BSA were added to a buffer (140 mM NaCl, 10 mM
Hepes, 2 mM CaCl
 
2
 
, and 1 mM EGTA, pH 7.2) containing per-
forin and one of the granzymes followed by incubation at 37
 
8
 
C
for the periods of time indicated in each experiment. In experi-
ments using peptide inhibitors, the cells were preincubated at
37
 
8
 
C for 30 min in the peptide before the addition of the per-
forin/granzyme mixture. Cells incubated with perforin and/or
granzymes were evaluated for apoptotic nuclei by chromatin
condensation by Hoechst 33258 or DAPI dye staining (10 nM in
PBS). Plasma membrane permeability as a measure of cell death
was determined by trypan blue dye exclusion. In both assays, be-
tween 150 and 300 cells were counted for each data point in
three independent assays, and the number of apoptotic or dead
cells was expressed as a percentage of the total cell number.
 
Flow Cytometry.
 
Changes in the 
 
Dc
 
 and the levels of reactive
oxygen species (ROS) in cells treated with granzymes and per-
forin was measured by two-color flow cytometry. The 
 
Dc
 
 was
measured with the mitochondria-specific fluorescent dye rho-
damine 123 (Rh123; 2 
 
m
 
M), and ROS levels were quantified by
the conversion of hydroethidine (2 
 
m
 
M) to ethidium. Both re-
agents were added for the final 30 min of the assay. Analysis was
performed using an EPICS 753 cell sorter (Coulter Corp.). No
fewer than 5,000 events were counted. Data was analyzed using
Coulter Elite workstation software (Coulter Corp.).
 
Immunofluorescence Microscopy.
 
Cytochrome 
 
c
 
 was detected in
HeLa or Rat-1 cells cultured on 12-mm diameter round cover-
slips overnight and then incubated with freshly titered Mi-
toTracker™ Green FM, usually 80 nM, (Molecular Probes) in
prewarmed culture medium for 30 min at 37
 
8
 
C for labeling. The
discs were washed three times with HBSS and soaked in 80 
 
m
 
l of
HBSS containing 10 mM Hepes, 2 mM CaCl
 
2
 
, and 4 mg/ml
BSA. In experiments using peptide inhibitors, the target cells
were pretreated for 15 min with zVAD-FMK, DEVD-CHO,
YVAD-CHO, or FA-FMK. 80-
 
m
 
l aliquots of GraB or GraK (2
 
m
 
g/ml) and perforin (125 ng/ml) in 140 mM NaCl, 10 mM
Hepes, and 1 mM EGTA, pH 7.2 were added to each coverslip.
After 3 h of incubation at 37
 
8
 
C, the cells were fixed in 3.7%
formaldehyde-PBS for 10 min. The cells were washed three
times with PBS and incubated with mouse monoclonal anti–cyto- 
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chrome 
 
c
 
 antibody (PharMingen) diluted in PBS containing 10%
FCS and 0.1% NP-40 for 1 h at room temperature with agitating.
After washing three times with PBS, the cells were incubated
with Cy3-conjugated goat anti–mouse antibody (Chemicon In-
ternational Inc., Don Mills, Ontario, Canada) diluted in the same
buffer for 1 h. The cells were washed three times in PBS and
mounted with 3 
 
m
 
l of Anti-Fade reagent (Bio-Rad) on a glass
slide. Image analysis was performed using a Zeiss Axiophot
microscope equipped with a cooled CCD camera and driven by
IPLabs Spectrum H-SU2 (version 3.0, Signal Analytics) and Mul-
tiprobe 1.1 E (Signal Analytics) software.
 
Western Blot Analysis.
 
Caspases were identified in postnuclear
lysates of perforin and granzyme-treated cells after SDS-PAGE
on a 15% agarose gel. Once the proteins were transferred to a ni-
trocellulose membrane, the blot was reacted with rabbit poly-
clonal antisera directed against the p17 fragment of CPP32/
caspase 3 (provided by D. Nicholson, Merck Laboratories, Mon-
treal, Canada). Pro-caspase 3 and its cleavage fragments were vi-
sualized by incubating the blot with horseradish peroxidase–con-
jugated goat anti–rabbit IgG antibody and developing with an
enhanced chemiluminescence kit according to the manufacturer’s
instructions (Amersham).
Cytochrome 
 
c
 
 was examined in lysates of target cells treated
with GraB and perforin. HeLa cells were harvested and washed
three times with HBSS and resuspended at 10
 
7
 
 cells/ml in 0.4%
BSA, 10 mM Hepes, 2 mM CaCl
 
2
 
, and HBSS, pH 7.2. Aliquots
of 5 
 
3
 
10
 
6
 
 target cells were added to 2 
 
m
 
g GraB and 80–120 ng
perforin was diluted in 140 mM NaCl, 10 mM Hepes, and 1 mM
EGTA, pH 7.2. in a total vol of 1 ml. In some experiments the
target cells were preincubated with 40 
 
m
 
M zVAD-FMK, 100
 
m
 
M YVAD-CHO, or 100 
 
m
 
M DEVD-CHO for 15 min at
room temperature. After 90 min of incubation at 37
 
8
 
C in an a
CO
 
2
 
 incubator, the cells were centrifuged to separate mitochon-
dria and mitochondria-free cytosol as described by Liu et al.
(24), except that the cells in a 0.3-ml vol were dounced 36 times
using a Teflon douncer to release mitochondria. Equal volumes
of the mitochondria-free cytosol and pooled pellet from the re-
maining fractions were subjected to 15% SDS-PAGE and trans-
ferred to a nitrocellulose filter. The filter was probed with mouse
anti–cytochrome 
 
c
 
 (PharMingen) and goat anti–mouse IgG-
horseradish peroxidase conjugate (Bio-Rad), and visualized by an
enhanced chemiluminescence method (Amersham).
 
In Vitro Cell-free System.
 
The preparation of S100 fractions
from HeLa or U937 cells was done as described by Liu et al. (24).
Nuclei from 2 
 
3 
 
10
 
8
 
 YAC-1, U937, or Jurkat cells were washed
three times with HBSS and resuspended in 2 ml NB buffer (10
mM Hepes-KOH, pH 7.5, 15 mM KCl, 2 mM MgCl
 
2
 
, 1 mM
dithiothreitol, 0.5 mM spermidine, 0.2 mM spermine, 1 
 
m
 
g/ml
leupeptin, 1 
 
m
 
g/ml aprotinin, and 0.5 mM PMSF). The cells
were put on ice for 20 min, which allowed them to swell, and
then were homogenized by 15 strokes of a douncing homoge-
nizer. The homogenate was centrifuged through a 4.5-ml cush-
ion of NB with 30% sucrose at 800 
 
g
 
 for 10 min. The pellets (nu-
clei) were washed once with NB and resuspended in storage
buffer (10 mM Hepes-KOH, pH 7.5, 80 mM KCl, 20 mM
NaCl, 250 mM sucrose, 5 mM EGTA, 1 mM dithiothreitol, 0.5
mM spermidine, 0.2 mM spermine, 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml
aprotinin, and 0.5 mM PMSF) at 10
 
8
 
 nuclei per milliliter and
were stored at 
 
2
 
80
 
8
 
C in multiple aliquots until use. Rat liver mi-
tochondria were isolated in 0.25 M sucrose as described by Pe-
dersen et al. (39). 20 
 
m
 
l HeLa S100, 10 
 
m
 
l diluted rat mitochondria
(100 
 
m
 
g/ml protein or as indicated) in dilution buffer (DB; 20
mM Hepes-KOH, pH 7.5, 2 mM MgCl
 
2
 
 and 1 mM dithiothre-
itol), 10 
 
m
 
l of diluted target nuclei in DB, and 10 
 
m
 
l purified
GraB diluted in 0.7 M NaCl, 10 mM bis-Tris, pH 6.0, was
placed in the cell-free apoptosis reaction mixture. After 1 h of in-
cubation in 37
 
8
 
C, the reaction mixture was fixed in 3.7% buff-
ered formaldehyde, stained with DAPI, and then apoptotic nuclei
were scored by microscopy with the identity of the slides con-
cealed to the reader.
 
Results
 
Perforin and Granzymes Induce 
 
Dc
 
 Suppression and ROS
Production.
 
In the presence of the pore-forming protein
perforin, GraB, but not GraK, rapidly activates apoptosis
and is highly Bcl-2 and Bcl-X
 
L
 
 inhibitable (Fig. 1, A and
B). GraB or GraK and sublytic amounts of perforin also in-
duce plasma membrane disruption and cell death (Fig. 1
C). To determine whether or not mitochondrial dysfunc-
tion is associated with granzyme- and perforin-dependent
cell death, tumor cell lines were treated with GraB or GraK
plus perforin and examined for loss of 
 
Dc
 
 and the genera-
tion of ROS using two-color flow cytometry with the flu-
orochrome Rh123 or hydroethidine, respectively (Fig. 2,
A–F). HeLa cells treated with either GraB or GraK in the
absence of perforin did not show any reduction in 
 
Dc
 
 or
ROS generation and were indistinguishable from untreated
controls (Fig. 2, A–C). In contrast, cells exposed to per-
forin alone exhibited a reduced 
 
Dc
 
 that was significantly
Figure 1. Induction of apop-
tosis by GraB and perforin. (A)
Rat-1 cells or Rat-1 cells over-
expressing Bcl-2 were treated
with increasing concentrations
of GraB or GraK and perforin
(80 ng/ml) for 3 h and then
the number of apoptotic nuclei
were counted after Hoechst
staining. (B) U937 cells over-
expressing Bcl-2 or Bcl-XL
were treated with GraB and
perforin and evaluated for apop-
totic nuclei as above. (C) HeLa
cells were treated with GraB or
GraK at the indicated concentrations and a constant amount of perforin (20 ng/ml) for 1 h and then dead cells were enumerated by trypan blue
exclusion. These data are representative of two or three similar experiments. 
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increased with the addition of either GraB (Fig. 2 E) or
GraK (Fig. 2 F). The perforin-mediated reduction in 
 
Dc
 
and ROS production was dose dependent. Addition of a
constant amount of either GraB or GraK to increasing
amounts of perforin greatly augmented the number of
 
Dc
 
low
 
 cells even at perforin concentrations too low to in-
duce any noticeable mitochondrial dysfunction (Fig. 3, A
and B). Treatment with perforin, or perforin and GraK,
also increased ROS levels in a dose-dependent manner
(Fig. 3 B). Similar results were obtained by repeating these
experiments with Jurkat cells. Surprisingly, ROS produc-
tion was not significantly increased by GraB plus perforin
treatment (Fig. 3 B). However, in other experiments cells
treated with lower doses of GraB did show increased levels
ROS, suggesting that, at the doses of GraB used here, tar-
get cells are sufficiently disrupted that their mitochondria
are unable to generate ROS.
We next determined the effects of PT inhibitors BA and
CsA on GraB-mediated apoptosis. CsA acts on matrix cy-
clophilin to prevent PT, and BA is a ligand of the adenine
nucleotide translocator and can inhibit preapoptotic 
 
Dc
 
disruption and apoptosis in isolated mitochondria (21). CsA
was without effect over a broad dose range on several tu-
mor targets. BA produced a six- to eightfold dose-depen-
dent inhibition of GraB-induced apoptosis of HeLa cells,
however its inhibitory effect on YAC-1 lymphoma was
minimal and never more than twofold (data not shown).
 
Bcl-2 Inhibits 
 
Dc
 
 Suppression and ROS Production Induced
by Perforin and Granzymes.
 
Bcl-2 and Bcl-X
 
L
 
 proteins pro-
mote cell survival and suppress cell death by many apoptotic
stimuli including GraB and perforin, and intact CTL gran-
ules (Fig. 1; references 35–37). Bcl-2 expression in the
outer mitochondrial membrane prevents mitochondrial PT
and 
 
Dc
 
 suppression and ROS production to many but not
all apoptotic signals (23). We next examined the effects of
Bcl-2 on these GraB and GraK-induced mitochondrial
changes. Rat-1 cells exposed to either of the granzymes
with perforin or just perforin alone exhibited reduced 
 
Dc
 
,
elevated ROS levels and increased numbers of dead cells
(Fig. 4, A–C). In contrast, Rat-1/Bcl-2 treated in exactly
the same way showed no 
 
Dc
 
low
 
 cells or generation of ROS
(Fig. 4, A and B) when compared with nontransfected con-
trol Rat-1 targets. The Bcl-2–expressing cells also exhib-
ited a significant reduction in the frequency of dead cells
induced by all of the stimuli including perforin alone, per-
forin and GraB, and perforin and GraK (Fig. 4 C). The
suppression of transmembrane potential to GraB was also
inhibited by overexpression of Bcl-X
 
L
 
 in U937 cells al-
though only by 
 
z
 
30–35% (data not shown), which is less
than that observed with Rat1/Bcl-2.
 
Release of Mitochondrial Cytochrome c after GraB/Perforin
Treatment and its Inhibition by Bcl-2 or Bcl-X
 
L
 
.
 
Cells under-
going apoptosis release cytochrome 
 
c
 
 from the mitochon-
Figure 2. Suppression of Dc and
ROS generation in HeLa cells
treated with GraB, GraK, and per-
forin. HeLa cells were treated with
GraB (B), GraK (2 mg/ml) (C), or
perforin (Perf) (20 ng/ml) (D) alone,
or combinations of GraB and per-
forin (E) or GraK and perforin (F)
for 1 h and then double stained with
the membrane potential sensitive
dye Rh123 plus hydroethidine (HE)
to assess ROS generation as de-
scribed in Materials and Methods.
Cells were then analyzed by flow
cytometry and illustrated on a loga-
rithmic scale. These data are repre-
sentative of three similar experi-
ments.
Figure 3. Suppression of Dc (A) and ROS generation (B) in HeLa cells
treated with GraB, GraK, and increasing concentrations of perforin. The
experiment was performed as described in Fig. 2 except that GraB and
GraK concentration was held constant at 2 mg/ml and the amount of per-
forin was added as indicated. These data are representative of two similar
experiments.135 MacDonald et al.
drial intermembranous space into the cytosol (27, 28, 40),
which is necessary for Apaf-1 activation of caspase 9 and
caspase 3 (28). Bcl-2 blocks cytochrome c release and
caspase 3 processing in a reconstituted cell free system, thus
it has been postulated that cytochrome c release is necessary
for downstream caspase activation and apoptosis (25–28).
We determined whether cell death signals mediated by
either perforin alone, or GraB/GraK plus sublytic amounts
of perforin are able to induce mitochondrial cytochrome c
release in intact cells following a 1-h incubation. We first
analyzed the subcellular localization of cytochrome c by
two-color analysis with anti–cytochrome c antibody (Fig. 5,
red) and the mitochondrial dye Mitotracker (Fig. 5, green)
which produce a yellow punctate pattern when they are
colocalized, but leave the mitochondria green when cyto-
chrome c is released. Simultaneous nuclear staining with
Hoechst dye detects chromatin condensation and apoptosis.
The pattern of cytochrome c immunofluorescence and nu-
clear Hoechst staining observed in HeLa cells treated with
GraK plus perforin or with perforin alone at sublytic doses
resembled untreated controls (Fig. 5 A). That is, cyto-
chrome c and the mitochondrial dye Mitotracker showed
complete colocalization and Hoechst staining of the nu-
cleus did not detect any apoptotic changes. In contrast, the
pattern of staining observed after treatment with GraB and
perforin revealed cells undergoing nuclear chromatin con-
densation, and mitochondria were stained with green Mi-
totracker but were no longer stained red for cytochrome c
(Fig. 5 B). Similar observations were made in Rat-1 and
MCF-7 cells (data not shown). We detected only faint lev-
els of cytochrome c in the cytoplasm, which may have been
too dispersed to detect by fluorescent microscopy or may
have been released from the cell as a result of plasma mem-
brane damage. In contrast to the above, Rat-1 cells consti-
tutively overexpressing Bcl-2 that were treated with GraB
and perforin showed no nuclear changes on Hoechst stain-
ing and normal mitochondrial cytochrome c localization,
identical to Fig. 5 A.
A time course, determined by counting cells retaining mi-
tochondrial cytochrome c immunofluorescence after treat-
ment with sublytic amounts of perforin plus GraB at vari-
ous times, demonstrated that cytochrome c was released
significantly before the appearance of apoptotic nuclei (Fig.
6). In experiments carried out over longer periods, the
number of apoptotic nuclei continued to increase and pla-
teau at the same level as cells showing cytochrome c redis-
tribution. In contrast, simultaneous assessment of Dc in the
same samples revealed that the appearance of Dclow cells
paralleled but did not precede apoptosis (Fig. 6).
We next confirmed these observations by Western blot-
ting cytochrome c released into the S100 cytosol. After
treatment with GraB and perforin, cytosolic cytochrome c
levels increased and this was not seen in cells over express-
ing Bcl-2 (Fig. 7 A). The release of cytochrome c in U937
cells was detected at lower doses of GraB than were able to
Figure 4. Bcl-2 inhibits the gen-
eration of Dclow cells, ROS, and cell
death induced by GraB, GraK, and
perforin. Rat-1 cells (black bars) or
Rat-1 cells over expressing Bcl-2
(white bars) were treated with GraB
(2 mg/ml), GraK (2 mg/ml), or per-
forin (Perf) (80 ng/ml) as indicated
for 1 h and then stained with (A)
Rh123 and (B) hydroethidine to
measure the percentage of Dclow or
high ROS-expressing cells, respec-
tively, as described in Fig. 2. The
percentage of dead cells (C) was
quantified after trypan blue staining.
The experiment is representative of
three similar experiments.
Figure 5. GraB and perforin induce the release of cytochrome c from
mitochondria detected by immunofluorescent localization. (A) Control
HeLa cells were triple stained with Mitotracker (green; left), which local-
izes in mitochondria and anti-cytochrome c antibody detected with Cy3-
conjugated second antibody (red; center). In the right panel the colors
were overlaid to illustrate colocalization of the Mitotracker and cyto-
chrome c in mitochondria (yellow). (B) HeLa cells were treated with
GraB (2 mg/ml) and perforin (80 ng/ml) for 1.5 h and then stained as in
A. Color overlay of all stains illustrates that cells undergoing apoptosis,
even in the earliest stages of chromatin margination (white arrows), have
no cytochrome c localized to the mitochondria leaving them stained only
for Mitotracker (green). Similar responses were observed in more than
five separate experiments.136 Mitochondrial Control of Granzyme B–induced Apoptosis
induce apoptosis (Fig. 7 B), and Bcl-2 and Bcl-XL over ex-
pression were equally effective in suppressing cytochrome c
release (Fig. 7 B). A time course showed that cytochrome c
appeared in S100 cytosol as early as 15 min after GraB and
perforin treatment but not with perforin treatment alone
(Fig. 7 C). The cleavage of caspase 3 was also detected
within 15 min before significant numbers of apoptotic cells
were detected (Fig. 7 D).
Peptide Caspase Inhibitors Block Apoptosis and Cytochrome c
Release But Not Dc Suppression. Earlier work indicated
that inhibition of caspases blocks GraB apoptosis (14, 17).
Since GraB activates both mitochondrial cytochrome c re-
lease and Dc suppression, we next examined the require-
ment for caspases in the induction of these mitochondrial
changes. Target cells were first incubated with increasing
amounts of the tetrapeptide caspase inhibitors that blocked
all caspases (zVAD-FMK), or those related to caspase 1
(YVAD-CHO) or caspase 3 (DEVD-CHO), then treated
with GraB and perforin to determine the dose of each that
would inhibit apoptosis by 70% (Fig. 8 A). Using pretreat-
ment with zVAD-FMK (40 mM) or YVAD-CHO (100
mM) under these conditions completely prevented cyto-
chrome c release from mitochondria as detected by immu-
nofluorescent localization (Fig. 8 B). However, cyto-
chrome c release was not blocked by the addition of
DEVD-CHO (100 mM) despite the nearly complete inhi-
bition of apoptosis, as clearly shown by intact Hoechst-
stained nuclei in cells with no mitochondrial cytochrome c
staining.
We next repeated the peptide inhibition experiments by
examining the release of cytochrome c into the cytosol
from mitochondria detected by Western blot. The appear-
ance of free cytosolic cytochrome c and the reduction of
Figure 6. Time course of the release of cytochrome c, appearance of Dclow
cells, and apoptosis in cells treated with GraB and perforin. (Left panel) Apop-
tosis versus Dc suppression. HeLa cells were treated with GraB (2 mg/ml) and
perforin (80 ng/ml) or perforin alone then Rh123 stained and Dclow cells an-
alyzed by flow cytometry. Cells from the same samples were Hoechst stained
for apoptotic cells. d, GraB/perforin-Dclow; s, perforin-Dclow; m, GraB/
perforin-apoptosis; n, perforin-apoptosis. (Right panel) Apoptosis versus cy-
tochrome c release. After treatment of HeLa cells with GraB and perforin or
perforin alone as described, cells were stained and the percentage releasing cy-
tochrome c from mitochondria (as illustrated in Fig. 5 B) was compared with
apoptotic nuclei. Virtually all cells undergoing apoptosis had released mito-
chondrial cytochrome c but not all cells releasing cytochrome c had apoptotic
nuclei. These samples were calculated from at least 200–300 cells and these
results are representative of three similar experiments, some of which ex-
tended to 4 h of observation. s, apoptosis-control; h, apoptosis-perforin; n,
apoptosis–GraB/perforin; d, cytochrome c release–control; j, cytochrome c
release–perforin; m, cytochrome c release–GraB/perforin.
Figure 7. (A) Bcl-2 inhibits the release of cytochrome c into
the cytosol after GraB and perforin treatment. Rat-1 or Rat-1/
Bcl-2 cells were incubated with GraB (2 mg/ml) and perforin
(80 ng/ml) or perforin alone for 1.5 h and then cells were
dounced and S100 cytosol was prepared by high speed centrifu-
gation as described in Materials and Methods. Cytosol fractions
were run on SDS-PAGE and Western blotted with anti–cyto-
chrome c antibody. The experiment was performed twice with
identical results. (B) Cytochrome c release and apoptosis with in-
creasing concentrations of GraB and perforin (80 ng/ml) in
U937, U937/Bcl-2, and U937/Bcl-XL. Cells were counted for
apoptotic nuclei by Hoechst staining and for mitochondrial cy-
tochrome c by immunofluorescence as described in Fig. 5. Re-
sults were essentially identical in three experiments taken after 3
or 4 h of incubation. (C) Western blot of cytochrome c release
and (D) caspase 3 processing after GraB and perforin treatment.
At the indicated times after treatment of HeLa cells with GraB
and perforin S100, mitochondrial fractions were prepared as de-
scribed in Materials and Methods and then Western blotted for
either cytochrome c or caspase 3.137 MacDonald et al.
mitochondrial cytochrome c levels was completely blocked
by zVAD-FMK and YVAD-CHO, whereas neither DEVD-
CHO nor the control FA-FMK had any effect on cy-
tochrome c release (Fig. 8 C). Thus, DEVD-CHO blocks
apoptosis independently of cytochrome c release, whereas
zVAD-FMK and YVAD-CHO appear to inhibit both cy-
tochrome c release and apoptosis.
Of additional interest, although zVAD-FMK (20 mM)
effectively blocked cytochrome c release, it did not suppress
the decrease in Dc or prevent the generation of ROS by
GraB and perforin treatment (Fig. 9, A and B). Further-
more, zVAD-FMK only partially inhibited GraB and was
unable to affect GraK-mediated cell death as measured by
trypan exclusion at a concentration that completely blocked
apoptosis as well as the proteolytic conversion of pro-
caspase 3 p32 to p17 (Fig. 9 C). Thus, the decrease in Dc
induced by GraB and perforin is not zVAD-FMK inhib-
itable and is therefore caspase independent.
Mitochondrial Regulation of GraB Apoptosis, and Caspase 3
Processing and Activation, in an In Vitro Cell-free System.
We next directly determined the role of mitochondria in
activating GraB apoptosis in an in vitro cell-free system.
Previously we had shown that the simple addition of GraB
without perforin to cell lysate initiates apoptosis of isolated
nuclei and this is associated with the processing and activa-
tion of caspase 3 (14). We now reexamined this model us-
ing mitochondria-free S100 cytosol. The absence of cyto-
chrome c on Western blotting confirmed that the S100 had
no contaminating mitochondria. GraB-induced apoptotic
activity is detectable without mitochondria (Fig. 10 A).
However, the addition of an enriched mitochondrial frac-
tion enhances apoptosis .15-fold with activity detectable
at 120 ng/ml of GraB. These experiments were repeated
using nuclei and S100 cytosol from several cellular sources,
including HeLa, YAC-1 or U937 cells, and mitochondria
from HeLa cells or rat liver with similar amplification of
apoptosis in the presence of mitochondria. The level of
amplification of GraB apoptosis by mitochondria was de-
pendent on the amount of enriched mitochondrial fraction
added to the reaction (Fig. 10 B). To confirm that the ac-
tivity was due to the proteolytic activity of GraB in our pu-
rified preparations, we used recombinant GraB bearing an
inactivating Ser203 to Ala mutation in the in vitro assay and
found that it was unable to initiate apoptosis in the pres-
ence or absence of mitochondria in contrast to wild-type
recombinant GraB (Fig. 10 C).
Figure 8. Inhibition of GraB-induced apopto-
sis and cytochrome c by caspase peptide inhibi-
tors. (A) HeLa cells preincubated with peptide
caspase inhibitors zVAD-FMK, YVAD-CHO,
DEVD-CHO, or FA-FMK at the indicated con-
centrations were treated with GraB (2 mg/ml)
and perforin (80 ng/ml) for 2.5 h and the apop-
totic nuclei were counted after Hoechst staining.
d, zVAD-FMK; ., YVAD-CHO; j, DEVD-
CHO; r, FA-FMK. (B) HeLa cells treated with
GraB (2 mg/ml) and perforin (80 ng/ml) for 1.5 h
were preincubated in zVAD-FMK (40 mM; cen-
ter panel), DEVD-CHO (100 mM; right panel),
or medium control (left panel) then stained as in
Fig. 5. The images show an overlay of the mito-
chondrial stains Mitotracker (green), cytochrome
c (red), and Hoechst (blue). Coincidence of cytochrome c and Mitotracker shows as yellow. Note that cells treated with DEVD-CHO have no evidence
of chromatin condensation (white arrows), yet cytochrome c no longer colocalizes with Mitotracker. Cells treated with YVAD-CHO (100 mM) were
identical to zVAD-FMK–treated cells (not shown). The concentrations of inhibitory peptide noted above inhibited apoptosis by 70% as determined in A.
(C) HeLa cells were treated with perforin alone (lanes 2 and 9) or GraB (2 mg/ml) and perforin (80 ng/ml; lanes 3–5, 9–11, and 14–16), staurosporine (1 mM;
lanes 6 and 12), or medium (lanes 1, 7, and 13) for 2.5 h. GraB- and perforin-treated cells were also preincubated in zVAD-FMK (40 mM; lanes 5, 11,
and 15), YVAD-CHO (100 mM; lane 16), or DEVD-CHO (100 mM; lanes 4 and 10) peptide inhibitors, control peptide FA-FMK (100 mM; lane 17),
or medium (lane 13) and cytochrome c in the S100 cytosolic fraction (lanes 7–17) and in the mitochondria-containing fractions assessed by Western blot-
ting (lanes 1–6). The doses of each inhibitory peptide reduced apoptosis by 70% (see A).138 Mitochondrial Control of Granzyme B–induced Apoptosis
We next determined whether caspase 3 processing and
activation by GraB requires mitochondria. S100 cytosol
and nuclei were incubated in increasing amounts of GraB
in the presence or absence of mitochondria as described
above then Western blotted for caspase 3. We found that in
the absence of mitochondria caspase 3 is clearly processed
to the p17-p22 products with 2,000 ng/ml GraB (Fig. 10
D). In the presence of mitochondria, GraB-induced cleav-
Figure 9. The effect of zVAD-FMK on cell death, caspase 3 processing, and suppression of Dc by GraB and per-
forin. (A) HeLa cells were treated with GraB or GraK at the indicated concentrations and a constant amount of per-
forin (80 ng/ml) for 1 h in the presence or absence of the general caspase inhibitor 40 mM zVAD-FMK then dead
cells enumerated by trypan blue exclusion. This experiment was repeated with the identical result. (B) HeLa cells
were treated with GraB at increasing doses and perforin (80 ng/ml) for 1 h in the presence of zVAD-FMK (40 mM)
(d) or medium (.) then evaluated after Rh123 and hydroethidine staining by flow cytometric analysis for the fre-
quency of Dclow cells and high ROS producing cells. This is representative of two similar experiments. (C) Caspase
3 processing in HeLa cells treated with GraB and perforin with or without zVAD-FMK pretreatment as in A. The
antibody recognizes the intact p32 caspase 3 as well as the cleaved p17 fragment of the activated caspase 3. This ex-
periment was repeated using a higher dose of perforin (100 ng/ml) and increasing amounts of GraB with the same
result (not shown). GraK and perforin did not produce caspase 3 processing after 1 h (not shown).
Figure 10. Amplification of GraB-induced apoptosis in an
in vitro cell free system. (A) GraB in increasing amounts was
added to S100 cytosol (s) or S100 cytosol plus mitochon-
dria (d) and nuclei for 1 h as described in Materials and
Methods. Nuclei were stained by Hoechst dye and apoptosis
was quantitated. The data are the mean 6 SE of three exper-
iments. (B) GraB in increasing amounts was added to S100
cytosol and nuclei with increasing amounts of mitochondria
(0, 40, 130, and 400 mg/ml mitochondrial protein), then in-
cubated for 1 h and apoptotic nuclei were enumerated as de-
scribed in A. Other experiments (A, C, and  D) contained
100 mg/ml mitochondrial protein. (C) Recombinant GraB
(rGrB; d) or GraB containing an Ser203 to Ala mutation [rGrB(S-A); s] were incubated with S100 cytosol, mitochondria, and nuclei as described in A.
(D) S100 caspase 3 processing after GraB treatment at increasing doses in the presence or absence of mitochondria (Mito). Incubations were carried out as
described in A and then cytosol was run on SDS-PAGE followed by Western blotting with anti–caspase 3 antibody. The dose of GraB increased from 0
(lanes 6 and 12) to 70 ng/ml (lanes 5 and 11), 200 ng/ml (lanes 4 and 10), 700 ng/ml (lanes 3 and 9), 2,000 ng/ml (lanes 2 and 8), and 6,000 ng/ml (lanes
1 and 7). The experiment was repeated three times with identical results.139 MacDonald et al.
age of caspase 3 was detected at 700 ng/ml, which is a
threefold decrease in the dose required to detect processing
(Fig. 10 D).
Discussion
This study demonstrates that activation of apoptosis by
GraB and perforin is invariably accompanied by mitochon-
drial perturbation, including the release of cytochrome c and
loss of mitochondrial transmembrane potential, and that
GraB requires the presence of mitochondria to efficiently
induce nuclear apoptosis in an in vitro cell-free system.
Disruption of Mitochondrial Transmembrane Potential by Gran-
zymes and Perforin. It has been postulated that Dc dis-
ruption is an early event in apoptosis and that it involves
the opening of the PT pores of the inner mitochondrial
membrane (21–23). Consistent with these data, we de-
tected Dc changes measured by the fluorochrome Rh123
or DiOC6 (data not shown) after GraB and perforin treat-
ment. However, we were unable to detect Dclow cells be-
fore the appearance of apoptotic nuclei or caspase 3 pro-
cessing. Similarly, the lack of effect of CsA and inconsistent
inhibition of apoptosis by BA in different target cells does
not support a model in which PT initiates GraB apoptosis.
However, we cannot exclude the possibility that PT may
contribute to the amplification or continuation of apoptosis
in some cells once they have been initiated by other signals.
We also find that the suppression of Dc is insufficient to
activate apoptosis. For example, perforin is unable to in-
duce apoptosis and produces a morphology more typical of
necrosis (2). The Dc suppression by perforin may be re-
lated to the necrosis-like injury it mediates, which is similar
to that associated with reperfusion injury after anoxia or
neuro- or hepatotoxins (41). Perforin forms a nonspecific
ion pore in the plasma membrane and induces a rapid in-
crease in intracellular Ca21 (42). Increases in cytosolic-free
Ca21 can themselves promote PT (43). Thus the Dc sup-
pression observed in perforin-treated cells may be second-
ary to this Ca21 influx, which we have found contributes
to the ability of perforin to induce cell death (42).
Another point of interest is that Dc suppression induced
by GraB, GraK, and perforin is not inhibited by the general
caspase inhibitor zVAD-FMK. Since GraB probably di-
rectly activates caspases to initiate the apoptotic pathway,
this is a surprising result and suggests that GraB may target
another noncaspase protein that controls mitochondrial
transmembrane potential. This caspase-independent path-
way is also able to induce cell death because the zVAD-
FMK inhibitor is only partially effective in blocking mem-
brane damage by GraB and sublytic perforin doses, while
completely inhibiting apoptosis at the same doses. Further-
more, zVAD-FMK has no effect on GraK or perforin-
induced cell death nor on Dc suppression (MacDonald, G.,
and A.H. Greenberg, data not shown). A caspase-indepen-
dent cell death pathway induced by cytotoxic T lympho-
cytes and GraB has been described (20, 44). The data
presented here suggest that GraB may target noncaspase cyto-
plasmic or mitochondrial proteins that lead to mitochon-
drial dysfunction and loss of transmembrane potential and
apparent disruption of electron transport with ROS pro-
duction. This caspase-independent mitochondrial pathway
is regulated by Bcl-2, as loss of Dc, ROS production, and
membrane damage induced by GraB, GraK, and perforin
are inhibited by Bcl-2 overexpression. Thus, we propose
that the disruption of mitochondrial function may be a part
of a caspase-independent pathway for granzyme- and per-
forin-mediated cell death.
Control of Mitochondrial Cytochrome c Release in GraB-
induced Apoptosis. As noted earlier, the release of cyto-
chrome  c by mitochondria has been postulated to be an im-
portant event in the activation of downstream caspases and
apoptosis (24–26, 40). The data presented in this paper are
consistent with the hypothesis that mitochondria are an im-
portant regulator of GraB-induced apoptosis. GraB induces
the release of mitochondrial cytochrome c at or before the
onset of the nuclear changes of apoptosis. Our experiments
show that caspase 3 processing and the release of cyto-
chrome c precede apoptosis by GraB and perforin treat-
ment, thus indicating a temporal and perhaps causal rela-
tionship. Furthermore, the release of cytochrome c into the
cytoplasm is blocked by either zVAD-FMK or YVAD-
CHO but not DEVD-CHO, suggesting that upstream
caspases propagate a signal that determines mitochondrial
cytochrome c release. Candidates include upstream caspases
6, 8, 9, and 10, and caspase 1–like proteases. Caspases 8 and
10 are upstream caspases that bear the preferred GraB
IEXD motif at the interchain processing site (4, 13) and
have been shown to be processed during GraB and CTL
apoptosis (20, 45), although caspase 10 is more readily pro-
cessed by GraB in vitro than are other caspases (20). Al-
though some cells derived from mice deficient in caspase 1
are more resistant to GraB (46), caspase 1 cannot be pro-
cessed by GraB directly in vitro (47). Thus, a YVAD-inhib-
itable caspase 1–like protease may participate in the path-
way but is probably not the primary target for GraB.
Alternatively, YVAD-CHO may be nonspecifically inhib-
iting another upstream caspase. It is also clear from these
experiments that a DEVD-CHO–inhibitable caspase con-
trols GraB apoptosis and resides downstream of the mito-
chondria by virtue of its inability to block cytochrome c
release. A model for caspases on the apoptotic pathway ly-
ing both upstream and downstream of mitochondria has
been proposed for Fas (23, 48).
We find that GraB/perforin-induced apoptosis is regu-
lated by Bcl-2 and Bcl-XL overexpression in agreement
with an earlier report (35). Both the release of cytochrome
c and caspase 3 processing are suppressed in Bcl-2 overex-
pressing cells. If Bcl-2/Bcl-XL suppress apoptosis primarily
by the inhibition of cytochrome c release at the mitochon-
dria then this would still allow GraB to interact with and
directly cleave caspase 3 in cells overexpressing Bcl-2/Bcl-
XL. However, Bcl-2 also completely prevents caspase 3
processing by GraB (Shi, L., and A.H. Greenberg, unpub-
lished data). In addition to its effects on cytochrome c
release, Bcl-XL acts by complexing with and preventing
Apaf-1/Ced-4 from activating caspase 9/Ced-3 (32, 33,140 Mitochondrial Control of Granzyme B–induced Apoptosis
49, 50), and therefore it is possible that caspases in a com-
plex with Bcl-2 and a Ced-4 like mammalian protein are
resistant to GraB proteolysis. At this time we cannot distin-
guish between the two potential mechanisms in which
Bcl-2 inhibits GraB activity, either through blocking cyto-
chrome c release or by physical interaction with a caspase
substrate, thereby preventing direct cleavage. Other inhibi-
tory mechanisms are possible, as Bcl-2/Bcl-XL can act at
sites other than mitochondria, including the endoplasmic
reticulum and downstream of mitochondria (51–53).
Although the inhibition of GraB-induced apoptosis is
clearly suppressed by Bcl-2/Bcl-XL, their regulation of
CTL is controversial. In some laboratories Bcl-2/Bcl-XL
appears to offer protection against killing mediated by
CTL, NK, or LAK cells using a granzyme/perforin- or
granule-mediated pathway (54–56). Others find little effect
on CTL or NK cell killing in cells overexpressing Bcl-2
(35, 57, 58). Recent experiments by Sutton et al. (35), in
which a comparative examination of susceptibility to apop-
tosis was made using the same cell lines, found a discordant
resistance to GraB/perforin-induced apoptosis and sus-
ceptibility to CTLs, NK cells, or isolated granules in Bcl-
2–expressing cells. These authors proposed that other gran-
ule components may provide the effector cells with the
means to bypass the Bcl-2 block. These might include
other granzymes such as GraA or GraK, which have been
shown to induce apoptosis in vitro and contribute to CTL
and NK killing alone or in combination with GraB (59–
61), or other granzymes in the CTL granules (62). The
molecular basis of the ability of CTLs to overcome Bcl-2
remains to be determined but this appears to be indepen-
dent of the action of GraB and perforin.
Another possibility is suggested by the observation that
Bcl-2 inhibition appears to distinguish two pathways of
Fas/CD95 killing (58). In this model, Bcl-2 can only in-
hibit receptor signals generated through mitochondria when
there is inefficient caspase 8 recruitment to the death-
inducing signaling complex (DISC). With efficient caspase
8 recruitment, mitochondria are bypassed, effector caspases
are activated directly, and Bcl-2 does not inhibit the pro-
cess. Since GraB killing appears to become more mito-
chondria-independent at higher doses, one could hypothe-
size that Bcl-2 would be less inhibitory in these conditions
because mitochondria are not necessary for apoptosis am-
plification. Thus CTLs expressing and delivering large
amounts of GraB to the target cell would be expected to
bypass mitochondria and be unaffected by Bcl-2 overex-
pression.
Mitochondria Amplify GraB-induced Apoptosis In Vitro.
Earlier models suggested that GraB can directly activate
caspase 3 to initiate cell death (17). Our data do show that
GraB can initiate the processing of caspase 3 in S100 cyto-
sol and that apoptosis is activated in the absence of mito-
chondria. Similar to earlier experiments in whole cell ly-
sates (14), caspase 3 in S100 cytosol is cleaved by the
addition of GraB. This indicates that a mitochondria-inde-
pendent caspase 3 processing and apoptosis mechanism ex-
ists. We cannot distinguish between direct or indirect pro-
teolysis of caspase 3. For example, it has been suggested by
other experiments that caspase 10 is a preferred substrate
(20), and thus GraB may also cleave caspase 3 indirectly via
caspase 10.
Although a mitochondria-independent pathway exists
for GraB apoptosis, it is clear that GraB induction of nu-
clear apoptotic activity is at least 15-fold greater in the pres-
ence of mitochondria. The apoptosis is dependent on the
amount of mitochondria in the incubation and only pro-
teolytically intact GraB is functional. The replacement of
the active Ser203 to an Ala completely eliminates GraB ac-
tivity in this reconstituted cell free system (shown in this
study) as well as in intact cells in the presence of perforin
(Shi, L., J. Lieberman, and A.H. Greenberg, data not
shown). The addition of mitochondria has a two to threefold
increase on the efficiency of caspase 3 processing by GraB
under the identical conditions that produce a much larger
(15-fold) increase in apoptosis. The relatively small enhance-
ment in caspase 3 processing was probably not sufficient to
account for the amplification of apoptosis, suggesting that
other caspases are recruited by mitochondria, which then
amplify apoptosis. That GraB may act through caspases other
than caspase 3 is suggested from the finding that GraB/per-
forin CTL effectors kill target cells from caspase 32/2 mice
and cleave poly (ADP-ribose) polymerase (PARP) with high
efficiency (45). In addition, MCF-7, which is caspase 3 de-
ficient (63), is susceptible to GraB- and perforin-induced
apoptosis (Shi, L., and A.H. Greenberg, unpublished data).
A mitochondria-regulated pathway would probably be di-
rected through caspase 9, which could then activate down-
stream caspases such as caspases 3 and 7. Alternatively, GraB
may induce the release of another mitochondrial protein that
Figure 11. Model of mitochondria-dependent and -independent con-
trol of apoptosis induced by GraB. An upstream zVAD-FMK– or
YVAD-CHO–inhibitable caspase is targeted by GraB, which then pro-
motes the release of mitochondrial cytochrome c. Cytochrome c release
and apoptosis are Bcl-2/Bcl-XL regulated. This mitochondrial pathway
activates caspase 3 and an unidentified but DEVD-CHO–inhibitable
caspase. A second mitochondria-independent pathway regulates caspase 3
processing and apoptosis and is also DEVD-CHO inhibitable. Caspase 3
may be directly activated by GraB or activated indirectly through an up-
stream caspase that is initially targeted by GraB.141 MacDonald et al.
can augment the nuclear apoptotic changes mediated by
the downstream effector caspases.
It is not clear from our data whether caspase 3 processing
or mitochondrial perturbation is the earlier event, since we
see simultaneous release of cytochrome c and caspase 3
cleavage after GraB/perforin treatment. For example, GraB
may first activate caspase 3 followed by a caspase 3–directed
initiation of the mitochondrial amplification mechanism to
further expand the processing of downstream caspases. It
has been observed recently that caspase 3 cleaves Bcl-2 and
Bcl-XL, which relieves their suppressive effects and allow
activation of apoptosis (64, 65). However, if caspase 3 acti-
vation preceded mitochondrial perturbation, then DEVD-
CHO inactivation of caspase 3 should block cytochrome c
release by GraB, which it does not under the conditions
of our experiments. The alternative interpretation is that
GraB targets an upstream caspase(s) that then triggers a mi-
tochondria-directed apoptosis pathway and the activation
of downstream caspases. A mitochondria-independent
pathway also exists in which GraB either directly cleaves
caspase 3, or does so through the processing of an upstream
caspase. The much greater activity observed in the presence
of mitochondria at lower GraB doses suggests that this is
the primary amplification pathway for apoptosis (see model
in Fig. 11).
In conclusion, we have identified the mitochondrial reg-
ulation of GraB-induced apoptosis. We suggest that GraB-
induced apoptosis is highly amplified by mitochondria in a
caspase-dependent manner but that GraB can also initiate
caspase 3 processing and apoptosis in the absence of mito-
chondria. We also propose that perforin alone or perforin
and granzymes induce caspase-independent mitochondrial
disruption and cell death.
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